Evidence map›Paper›PMID 38506662›Full record

ArticleCancer research communications2024

Identification of Enhanced Vaccine Mimotopes for the p15E Murine Cancer Antigen.

Shiqi Zhou, Yiting Song, Yuan Luo, Breandan Quinn, Yang Jiao, Mark D Long, Scott I Abrams, Jonathan F Lovell

Open access · goldAbstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shiqi ZhouDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York.ORCID 0000-0002-0530-9512
Yiting SongDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York.ORCID 0009-0001-6429-4293
Yuan LuoDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York.ORCID 0009-0008-8582-2519
Breandan QuinnDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York.ORCID 0000-0002-0165-4650
Yang JiaoDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York.ORCID 0009-0004-3518-6471
Mark D LongDepartment of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0003-1120-8176
Scott I AbramsDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York.ORCID 0000-0002-8742-4708
Jonathan F LovellDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, New York.ORCID 0000-0002-9052-884X
University at Buffalo, State University of New York · USRoswell Park Comprehensive Cancer Center · US

Funding

A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide VaccinesR01CA247771 · NCI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI ABRAMS, SCOTT I., LOVELL, JONATHAN F · 2020 to 2024
$1.9M
NCI NIH HHS R01 CA247771
6 · The paper itself

Abstract

Mimotopes of short CD8+ T-cell epitopes generally comprise one or more mutated residues, and can increase the immunogenicity and function of peptide cancer vaccines. We recently developed a two-step approach to generate enhanced mimotopes using positional peptide microlibraries and herein applied this strategy to the broadly used H-2Kb-restricted murine leukemia p15E tumor rejection epitope. The wild-type p15E epitope (sequence: KSPWFTTL) was poorly immunogenic in mice, even when combined with a potent peptide nanoparticle vaccine system and did not delay p15E-expressing MC38 tumor growth. Following positional microlibrary functional screening of over 150 mimotope candidates, two were identified, both with mutations at residue 3 (p15E-P3C; "3C," and p15E-P3M; "3M") that better induced p15E-specific CD8+ T cells and led to tumor rejection. Although 3M was more immunogenic, 3C effectively delayed tumor growth in a therapeutic setting relative to the wild-type p15E. As 3C had less H-2Kb affinity relative to both p15E and 3M, 15 additional mimotope candidates (all that incorporated the 3C mutation) were assessed that maintained or improved predicted MHC-I affinity. Valine substitution at position 2 (3C2V, sequence: KVCWFTTL) led to improved p15E-specific immunogenicity, tumor rejection, and subsequent long-term antitumor immunity. 3C, 3M, and 3C2V mimotopes were more effective than p15E in controlling MC38 and B16-F10 tumors. T-cell receptor (TCR) sequencing revealed unique TCR transcripts for mimotopes, but there were no major differences in clonality. These results provide new p15E mimotopes for further vaccine use and illustrate considerations for MHC-I affinity, immunogenicity, and functional efficacy in mimotope design. SIGNIFICANCE: The MHC-I-restricted p15E tumor rejection epitope is expressed in multiple murine cancer lines and is used as a marker of antitumor cellular immunity, but has seen limited success as a vaccine immunogen. An in vivo screening approach based on a positional peptide microlibraries is used to identify enhanced p15E mimotopes bearing amino acid mutations that induce significantly improved functional immunogenicity relative to vaccination with the wild-type epitope.

Indexed as

NeoplasmsVaccinesAnimalsEpitopes, T-LymphocyteMicePeptidesReceptors, Antigen, T-CellEpitopes, T-LymphocytePeptidesReceptors, Antigen, T-CellVaccines

Identifiers

PMID38506662
PMCPMC10986479
OpenAlexW4393026261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.